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In two interim analyses of this trial, patients with advanced heart failure who were
treated with a fully magnetically levitated centrifugal-flow left ventricular assist
device were less likely to have pump thrombosis or nondisabling stroke than were
patients treated with a mechanical-bearing axial-flow left ventricular assist device.
METHODS

We randomly assigned patients with advanced heart failure to receive either the
centrifugal-flow pump or the axial-flow pump irrespective of the intended goal of
use (bridge to transplantation or destination therapy). The composite primary end
point was survival at 2 years free of disabling stroke or reoperation to replace or
remove a malfunctioning device. The principal secondary end point was pump
replacement at 2 years.
RESULTS

This final analysis included 1028 enrolled patients: 516 in the centrifugal-flow
pump group and 512 in the axial-flow pump group. In the analysis of the primary end point, 397 patients (76.9%) in the centrifugal-flow pump group, as
compared with 332 (64.8%) in the axial-flow pump group, remained alive and free
of disabling stroke or reoperation to replace or remove a malfunctioning device at
2 years (relative risk, 0.84; 95% confidence interval [CI], 0.78 to 0.91; P<0.001 for
superiority). Pump replacement was less common in the centrifugal-flow pump
group than in the axial-flow pump group (12 patients [2.3%] vs. 57 patients
[11.3%]; relative risk, 0.21; 95% CI, 0.11 to 0.38; P<0.001). The numbers of events
per patient-year for stroke of any severity, major bleeding, and gastrointestinal
hemorrhage were lower in the centrifugal-flow pump group than in the axial-flow
pump group.
CONCLUSIONS

Among patients with advanced heart failure, a fully magnetically levitated centrifugalflow left ventricular assist device was associated with less frequent need for pump
replacement than an axial-flow device and was superior with respect to survival
free of disabling stroke or reoperation to replace or remove a malfunctioning device.
(Funded by Abbott; MOMENTUM 3 ClinicalTrials.gov number, NCT02224755.)
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T

he use of left ventricular assist
devices in patients with advanced-stage
heart failure is beleaguered by hemocompatibility-related complications of thrombosis,
stroke, and bleeding, which are consequences of
adverse interactions between the pump and circulating blood elements.1 Advances in bioengineering have led to the introduction of durable continuous-flow left ventricular assist devices, but
concerns have been raised about the risk of pump
thrombosis causing device malfunction.2 The shear
stress created by continuous-flow pumps also
leads to degradation of high-molecular-weight
multimers of von Willebrand factor, a phenomenon that has been implicated in the development
of mucosal arteriovenous malformations and
bleeding.3,4 In addition, a high frequency of stroke
remains a serious concern for patients who receive a left ventricular assist device.5
The most widely implanted left ventricular assist device, the Heartmate II (Abbott), is an axial
continuous-flow pump, which requires thoraco
abdominal placement.6 An intrapericardial centrifugal-flow pump, the HVAD (Medtronic), was found
to be noninferior to the HeartMate II device with
regard to survival but was associated with a higher
incidence of stroke.7 A fully magnetically levitated
centrifugal-flow intrathoracic left ventricular assist device, the HeartMate 3 (Abbott), has been
engineered with wide blood-flow pathways, friction-free movement, and intrinsic pulsatility to
reduce shear stress and stasis of blood.8
In the Multicenter Study of MagLev Technology
in Patients Undergoing Mechanical Circulatory
Support Therapy with HeartMate 3 (MOMENTUM
3), the HeartMate 3 centrifugal-flow left ventricular assist device was compared with the HeartMate
II axial-flow device, either as a bridge to transplantation or as destination therapy, in 1028 patients
with advanced-stage heart failure.9 We previously reported prespecified 6-month and 2-year
interim outcomes in smaller trial cohorts from
MOMENTUM 3 (294 and 366 patients, respectively).9-11 These analyses showed a lower incidence of
pump thrombosis leading to malfunction with the
centrifugal-flow pump than with the axial-flow
device. The 2-year interim analysis also suggested
a lower incidence of nondisabling stroke with the
centrifugal-flow pump.11 We now provide the final report of efficacy and safety end points in the
full trial population (Fig. S1 in the Supplementary

n engl j med 380;17

Appendix, available with the full text of this article at NEJM.org).

Me thods
Trial Design

In this randomized trial, we compared a centrifu
gal-flow left ventricular assist device with an
axial-flow device in patients with advanced-stage
heart failure. Details of the trial design have
been published previously.9-11 The protocol was
approved by each institutional review board at
69 participating centers in the United States. The
trial was sponsored by Abbott, which provided
the devices, selected the sites, and analyzed the
data (as indicated in the Supplementary Appendix),
with verification performed by an independent
statistician. The authors vouch for the completeness and accuracy of all the data and analyses
and for fidelity of the trial to the protocol, which
is available at NEJM.org.
Trial Population

We enrolled patients with advanced-stage heart
failure who were deemed to be candidates for
therapy with a left ventricular assist device, irrespective of whether the intended goal was to provide support as a bridge to transplantation or as
destination therapy. Patients were excluded from
the trial if biventricular circulatory support was
expected to be necessary or if irreversible endorgan dysfunction or active infection was present. Written informed consent was obtained from
all patients or their authorized representatives.
Detailed inclusion and exclusion criteria are provided in the Supplementary Appendix.
Randomization and Data Collection

Patients were randomly assigned in a 1:1 ratio to
receive either the centrifugal-flow pump or the
axial-flow pump. Randomization was performed
with the use of permuted blocks and stratification
according to study center and was implemented
with the use of an electronic data-capture system
(eClinicalOS, Merge Healthcare). The investigators
and patients were aware of the treatment assignments. Data on end points and adverse events
were collected after implantation at 1 day, 1 week,
discharge, 1 month, 3 months, 6 months, and then
every 6 months until 2 years of follow-up had
been completed.
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The two left ventricular assist devices used were
the HeartMate 3 fully magnetically levitated centrifugal continuous-flow pump and the HeartMate II mechanical-bearing axial continuous-flow
pump. All the investigators were experienced in
the use of the control axial-flow pump and underwent training before their first implantation
of a centrifugal-flow pump. The recommended
antithrombotic treatment in each group included
aspirin at a dose of 81 to 325 mg daily and warfarin (target range for the international normalized
ratio, 2.0 to 3.0).
End Points

The composite primary end point was survival at
2 years free of disabling stroke or reoperation to
replace or remove a malfunctioning device. In
the analysis of the primary end point, disabling
stroke was defined by a modified Rankin score
of greater than 3 (scores range from 0 to 6, with
higher scores indicating greater disability). The
principal secondary end point, which the trial was
separately powered to assess, was pump replacement at 2 years after implantation. Other secondary end points included actuarial survival, rehospitalization, functional status, and quality of life.
Subgroup analyses were prespecified for age, sex,
race, intended goal of therapy (bridge to transplantation or destination therapy), and severity of illness at baseline.
The rates of major adverse events such as
stroke, bleeding, right heart failure, and infection
were also evaluated (definitions are provided in the
Supplementary Appendix). An independent clinical-events committee, the members of which were
unaware of the treatment assignments, adjudicated the causes of death and bleeding, infection,
neurologic dysfunction, suspected device thrombosis, and hemolysis. A 6-minute walk test administered by a trained technician and New York
Heart Association (NYHA) classification were used
to evaluate functional status. Quality of life was
assessed with the European Quality of Life–5 Dimensions (EQ-5D) 5-Level questionnaire (EQ-5D5L), the EQ-5D visual-analogue scale (EQ-5D VAS),
and the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Statistical Analysis

The sample size for the full cohort of patients who
underwent randomization was calculated to test
1620
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whether the centrifugal-flow left ventricular assist device was superior to the axial-flow left ventricular assist device with respect to the percentage of patients undergoing pump replacement at
2 years. We determined that, with 7% of patients
in the axial-flow pump group and 3% of patients
in the centrifugal-flow pump group expected to
have undergone pump replacement at 2 years,
1028 patients would be required to show superiority with a power of 80% and an alpha of 0.05
(two-sided) (details are provided in the Supplementary Appendix).
The primary end point was analyzed in the
intention-to-treat population, which included all
patients who underwent randomization. Patients
were considered to have had treatment failure with
respect to the primary end point if any of the following events occurred: withdrawal from the trial
before implantation (i.e., the patient underwent
randomization but did not undergo implantation
of the assigned device), withdrawal from the trial
after implantation, death, disabling stroke, any
pump replacement, urgent transplantation for device malfunction, or pump explantation or permanent deactivation for a reason other than myocardial recovery. If a patient had more than one of
these events, the event that occurred first was
noted as the treatment-failure event in the analysis
of the primary end point. Transplantation for reasons other than device malfunction and pump
explantation or permanent deactivation for myocardial recovery were not considered treatmentfailure events.
Noninferiority with regard to the primary end
point would be shown if the lower 95% confidence
boundary of the difference between the treatment
groups (centrifugal-flow pump minus axial-flow
pump) in the percentage of patients remaining
alive and free of disabling stroke or reoperation
to replace or remove a malfunctioning device at
2 years was numerically greater than −10 percentage points (i.e., closer to or greater than zero)
with a two-tailed P value of less than 0.05, calculated by the Farrington–Manning risk-difference approach. If noninferiority was met, then
superiority was evaluated with the z test of proportions, with the use of the normal approximation to the binomial distribution. Relative risks
and 95% confidence intervals for the primary
end point and its component events are shown,
and actuarial event-free survival was calculated
by the Kaplan–Meier method.
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All secondary end points were analyzed in the
per-protocol population, which included all patients who underwent randomization and received
the assigned device. The principal secondary end
point was analyzed with Fisher’s exact test. Poisson regression was used to compare the rates of
major adverse events between the two treatment
groups as numbers of events per patient-year.
The rate differences are described as relative risks
with the corresponding 95% confidence intervals.
The incidence of rehospitalization in discharged
patients was evaluated with the Andersen–Gill
model. Overall survival was analyzed by the Kaplan–Meier method, with data censored for nonfatal outcomes, such as transplantation. Hazard
ratios were calculated from Cox proportionalhazards models. Longitudinal changes in functional status and quality of life were analyzed by
means of linear mixed-effects modeling.
The reported P values for the primary and principal secondary end point are two-tailed. The 95%
confidence intervals have not been adjusted for
multiplicity, and therefore inferences drawn from
these intervals may not be reproducible. Statistical analyses were performed with the use of SAS
software, version 9.4 or higher (SAS Institute).

R e sult s
Patients and Device Implantation

From September 2014 through August 2016, a
total of 1028 patients underwent randomization
(516 patients to the centrifugal-flow pump group
and 512 patients to the axial-flow pump group)
(Fig. S2 in the Supplementary Appendix). The baseline characteristics of the patients are shown in
Table 1, and in Table S1 in the Supplementary
Appendix.
One patient who had been assigned to receive
the centrifugal-flow pump and 7 who had been
assigned to receive the axial-flow pump did not
undergo implantation per protocol. The remaining patients (per-protocol population) included
515 who underwent implantation of a centrifugalflow pump and 505 who underwent implantation of an axial-flow pump. A total of 126 surgeons
performed 1020 implantations at 69 sites.

in the centrifugal-flow pump group than in the
axial-flow pump group remained alive and free
of disabling stroke or reoperation to replace or
remove a malfunctioning device at 2 years (397
patients [76.9%] vs. 332 patients [64.8%]). The
noninferiority criterion (absolute between-group
difference, 12.1 percentage points; 95% confidence
interval [CI], 6.0 to 18.2; P<0.001) and superiority
criterion (relative risk, 0.84; 95% CI, 0.78 to 0.91;
P<0.001) were met. Details of the primary endpoint components according to the first treatment-failure event that occurred are shown in
Table 2, and in Table S2 in the Supplementary
Appendix.
In a worst-case sensitivity analysis, patients in
the axial-flow pump group who withdrew from
the trial before or after implantation or who underwent urgent heart transplantation for device
malfunction were considered to have had treatment success, whereas such patients in the centrifugal-flow pump group were still considered to
have had treatment failure (Table S3 in the Supplementary Appendix). The result of this analysis
was similar to that of the primary end-point analysis (relative risk, 0.91; 95% CI, 0.84 to 0.98). The
Kaplan–Meier estimates of actuarial event-free
survival at 2 years (primary end point) in the intention-to-treat population were 74.7% in the centrifu
gal-flow pump group and 60.6% in the axial-flow
pump group (Fig. 1).
The principal secondary end point of pump
replacement at 2 years occurred less frequently in
the centrifugal-flow pump group than in the
axial-flow pump group (12 patients [2.3%] vs.
57 patients [11.3%]; relative risk, 0.21; 95% CI,
0.11 to 0.38; P<0.001) (Table 2). A list of the specific reasons for pump replacement in each group
is provided in Table S4 in the Supplementary
Appendix.
Clinical Course

Discharge from the hospital with the device in
place occurred in 485 of 515 patients (94.2%) in
the centrifugal-flow pump group and 471 of 505
(93.3%) in the axial-flow pump group. The median
length of stay during the hospitalization for implantation was 19 days in the centrifugal-flow
pump group and 17 days in the axial-flow pump
End Points
group. The median number of days of rehospitalAll patients were followed for 2 years, and no end- ization, days spent outside the hospital receiving
point data were missing. In the analysis of the left ventricular assist device support, and all-cause
primary end point, a larger percentage of patients rehospitalization rates are shown in Table 3.
n engl j med 380;17
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Table 1. Baseline Characteristics of Patients in the Intention-to-Treat Population.*
Centrifugal-Flow Pump Group
(N = 516)

Axial-Flow Pump Group
(N = 512)

59±12

60±12

Median (range)

62 (18–83)

63 (21–84)

Male sex — no. (%)

411 (79.7)

419 (81.8)

White

342 (66.3)

367 (71.7)

Black

145 (28.1)

120 (23.4)

Asian

8 (1.6)

3 (0.6)

Characteristic
Age — yr
Mean

Race or ethnic group — no. (%)†

Native Hawaiian or Pacific Islander
Other
Body-surface area — m2

0

4 (0.8)

21 (4.1)

18 (3.5)

2.1±0.3

2.1±0.3

Ischemic cause of heart failure — no. (%)

216 (41.9)

240 (46.9)

History of atrial fibrillation — no. (%)

215 (41.7)

238 (46.5)

50 (9.7)

56 (10.9)

102 (19.8)

114 (22.3)

36 (7.0)

31 (6.1)

17.3±5.1

17.2±5.0

Systolic

108.4±14.7

106.5±14.5

Diastolic

66.8±10.6

65.7±10.2

Mean arterial pressure — mm Hg

79.2±10.4

79.2±10.1

Pulmonary-capillary wedge pressure — mm Hg

23.1±8.6

22.9±9.2
2.0±0.6

History of stroke — no. (%)
Previous cardiac surgical procedures — no. (%)
Coronary-artery bypass
Valve replacement or repair
Left ventricular ejection fraction — %
Arterial blood pressure — mm Hg

2

Cardiac index — liters/min/m

2.0±0.5

Pulmonary vascular resistance — Wood units

3.1±1.7

3.0±1.7

Right atrial pressure — mm Hg

10.8±6.5

10.7±6.8

Serum sodium level — mmol/liter

135.4±4.1

135.5±4.2

1.4±0.4

1.4±0.4

61.3±23.7

59.5±22.0

113 (21.9)

121 (23.6)

86 (16.7)

81 (15.8)

317 (61.4)

310 (60.5)

Serum creatinine level — mg/dl
2

Estimated glomerular filtration rate — ml/min/1.73 m
Intended goal of pump support — no. (%)
Bridge to transplantation
Bridge to candidacy for transplantation
Destination therapy

*	Plus–minus values are means ±SD. There were no significant differences between the groups in any characteristic except for race (P = 0.04) and systolic blood pressure (P = 0.03). The intention-to-treat population included all patients
who underwent randomization. Data on Interagency Registry for Mechanically Assisted Circulatory Support
(INTERMACS) profiles and concomitant medications and cardiac interventions are provided in Table S1 in the
Supplementary Appendix. Percentages may not total 100 because of rounding. To convert the serum creatinine level to
micromoles per liter, multiply by 88.4.
†	Race or ethnic group was reported by the patient.
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Underwent reoperation to replace or remove pump¶

Had disabling stroke‖

Died within 24 months after implant**
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2.3 (1.2–4.0)

15.5 (12.5–18.9)

3.9 (2.4–5.9)

2.7 (1.5–4.5)

0.8 (0.2–2.0)

0.2 (0.0–1.1)

76.9 (73.1–80.5)

76.9 (73.1–80.5)

% (95% CI)

57

67

30

73

3

7

332

332

no. of
patients

11.3 (8.7–14.4)

13.1 (10.3–16.3)

5.9 (4.0–8.3)

14.3 (11.4–17.6)

0.6 (0.1–1.7)

1.4 (0.6–2.8)

64.8 (60.5–69.0)

64.8 (60.5–69.0)

% (95% CI)

Axial-Flow Pump Group
(N = 512)

12.1 (6.0)

percentage points
(95% LCB)

Absolute
Difference

0.21 (0.11–0.38)

1.18 (0.88–1.60)

0.66 (0.38–1.15)

0.19 (0.11–0.33)

1.32 (0.30–5.88)

0.14 (0.02–1.15)

0.84 (0.78–0.91)

Relative Risk
(95% CI)

<0.001‡‡

<0.001‡

<0.001‡

P Value

*	The 95% confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible. LCB denotes lower confidence
boundary.
†	The primary end point was a composite of survival free of disabling stroke or reoperation to replace or remove a malfunctioning device at 24 months after implantation. Disabling
stroke was defined by a modified Rankin score of greater than 3 (scores range from 0 to 6, with higher scores indicating more severe disability). The intention-to-treat population included all patients who underwent randomization.
‡	P values for the primary end-point analyses are from Farrington–Manning risk difference (in the noninferiority analysis) or the z test of proportions with normal approximation to the
binomial distribution (in the superiority analysis).
§	The event that occurred first was noted as the treatment-failure event in this component analysis. Patients could have multiple events after the first event leading to treatment failure
with regard to the primary end point (e.g., disabling stroke after a pump exchange), which are not accounted for in the primary analysis. Table S2 in the Supplementary Appendix
shows this in the context of disabling strokes and deaths as first events or recurrent events.
¶	For the component analysis, this category includes pump replacement (12 patients in the centrifugal-flow pump group and 56 in the axial-flow pump group), urgent heart transplantation for device malfunction (2 patients in the centrifugal-flow pump group and 15 in the axial-flow pump group), or explantation or permanent deactivation of the device for a reason
other than myocardial recovery (2 patients in the axial-flow pump group). There were 57 patients in the axial-flow pump group who underwent pump replacement; 56 pump replacements in the axial-flow pump group were first events that led to treatment failure in a patient with regard to the primary end point.
‖	There were 26 patients in the centrifugal-flow pump group and 38 patients in the axial-flow pump group who had a disabling stroke; the corresponding rates of disabling stroke for the
treatment groups were 0.04 events per patient-year and 0.07 events per patient-year. Among all the disabling stroke events, 20 in the centrifugal-flow pump group and 30 in the axialflow pump group were first events that led to treatment failure in a patient with regard to the primary end point.
**	A total of 98 patients in the centrifugal-flow pump group and 103 patients in the axial-flow pump group had died at 2 years; 80 deaths in the centrifugal-flow pump group and 67
deaths in the axial-flow pump group were first events that led to treatment failure in a patient with regard to the primary end point.
††	The secondary end point was evaluated in the per-protocol population (515 patients in the centrifugal-flow pump group and 505 patients in the axial-flow pump group) for the first
event of pump replacement.
‡‡	The P value for the principal secondary end point was calculated with Fisher’s exact test.

Pump replacement within 24 months after implantation

12

14

Withdrew after implantation

Principal secondary end point††

1
4

Withdrew before implantation

First event that resulted in treatment failure with respect to
the primary end point§

397

Superiority analysis

no. of
patients

Centrifugal-Flow Pump Group
(N = 516)

Noninferiority analysis

Primary end point†

End Point

Table 2. Primary and Principal Secondary End Points.*
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Table 3. Postdischarge End Points among Patients Discharged while Receiving Left Ventricular Assist Device Support (Per-Protocol
Population).*
Centrifugal-Flow
Pump Group
(N = 485)

End Point
Median duration of rehospitalization (interquartile range) — days

Axial-Flow
Pump Group
(N = 471)

Difference or
Hazard Ratio (95% CI)

13 (4 to 37)

18 (6 to 40)

−5 (−8.7 to −1.3)

Median duration receiving left ventricular assist device support
outside hospital (interquartile range) — days

653 (333 to 696)

605 (259 to 690)

48 (−0.8 to 96.8)

Rate of rehospitalization for any cause — events per patient-yr

2.26

2.47

0.92 (0.86 to 0.99)†

*	The per-protocol population included all patients who underwent randomization and received the assigned device. The 95% confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible.
†	The hazard ratio was derived from the Andersen–Gill model for the comparison of all-cause readmissions between the groups.

There were 98 deaths in the centrifugal-flow
pump group and 103 in the axial-flow pump group
after implantation, with no significant difference
in overall survival between the groups (Fig. S3 in
the Supplementary Appendix). The most common
causes of death among the patients with either
device were right heart failure, stroke, and infection (Table S5 in the Supplementary Appendix).

Percentage of Patients
with Event-free Survival

100
90

87.9

80

82.7

70

84.0

Centrifugal-flow
pump

74.7

74.8

60

Axial-flow
pump

50

60.6

40
30
20
Hazard ratio, 0.60 (95% CI, 0.47–0.75)

10
0

0

6

12

18

24

Months since Implantation
No. at Risk
Centrifugal-flow pump 516
Axial-flow pump
512

438
401

373
321

313
264

280
223

Figure 1. Kaplan–Meier Estimates of the Primary End Point in the Intentionto-Treat Population.
The intention-to-treat population included all patients who underwent randomization. The primary end point was a composite of survival free of disabling stroke or reoperation to replace or remove a malfunctioning device
at 24 months after implantation. Disabling stroke was defined by a modified Rankin score of greater than 3 (scores range from 0 to 6, with higher
scores indicating more severe disability). Kaplan–Meier estimates for the
primary end point at 6, 12, and 24 months are shown. The 95% confidence
intervals have not been adjusted for multiplicity, and therefore inferences
drawn from these intervals may not be reproducible.
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Competing-risk curves that reflect the cumulative
percentages of patients in each group who had an
outcome of ongoing device support, transplantation, device explantation or deactivation, or death
through 2 years are shown in Figure S4 in the
Supplementary Appendix.
Safety Outcomes

Between-group comparisons of event rates for
hemocompatibility-related adverse events (including pump thrombosis, stroke, and bleeding) and
other major events are shown in Figure 2. Instantaneous hazard risk curves are shown in Figure S5
in the Supplementary Appendix. There were 70
cases of suspected or confirmed pump thrombosis with the axial-flow pump and 7 cases with the
centrifugal-flow pump; narratives of these events
with the centrifugal-flow pump are provided in the
Supplementary Appendix. Data on other major
adverse events are shown in Figure S6 and Tables S6 and S7 in the Supplementary Appendix.
Ventricular arrhythmias were less frequent with
the centrifugal-flow pump than with the axialflow device.
There were no significant differences between
the groups with respect to clinical factors associated with stroke risk, including history of atrial
fibrillation, history of stroke, maintenance of mean
arterial blood pressure at or below 90 mm Hg, or
receipt of antithrombotic therapy during the trial.
Lactate dehydrogenase levels were lower in the
centrifugal-flow pump group than in the axialflow pump group. Details of these analyses and
data regarding hepatic and renal function are provided in Table 1, and in Tables S8 through S10 and
Figure S7 in the Supplementary Appendix.
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Adverse Event

CentrifugalFlow
Pump

AxialFlow
Pump

CentrifugalFlow
Pump

no. of patients with events (%)
Suspected or confirmed pump
thrombosis
Any stroke
Disabling stroke
Any bleeding
Gastrointestinal bleeding
Other neurologic event
Any major infection
Right heart failure
Cardiac arrhythmia
Respiratory failure
Renal dysfunction
Hepatic dysfunction

AxialFlow
Pump

Relative Risk (95% CI)

P Value

events per patient-yr

7 (1.4)

70 (13.9)

0.01

0.12

0.08 (0.04–0.16)

<0.001

51 (9.9)
26 (5.0)
225 (43.7)
126 (24.5)
59 (11.5)
300 (58.3)
176 (34.2)
185 (35.9)
111 (21.6)
73 (14.2)
25 (4.9)

98 (19.4)
38 (7.5)
278 (55.0)
156 (30.9)
47 (9.3)
285 (56.4)
143 (28.3)
207 (41.0)
98 (19.4)
56 (11.1)
27 (5.3)

0.08
0.04
0.61
0.31
0.09
0.82
0.27
0.37
0.19
0.11
0.03

0.18
0.07
0.95
0.49
0.08
0.82
0.23
0.45
0.17
0.08
0.04

0.42 (0.30–0.57)
0.54 (0.34–0.85)
0.64 (0.57–0.72)
0.64 (0.54–0.75)
1.25 (0.88–1.79)
1.00 (0.89–1.12)
1.15 (0.94–1.42)
0.82 (0.70–0.97)
1.10 (0.86–1.40)
1.36 (0.98–1.89)
0.78 (0.46–1.34)

<0.001
0.008
<0.001
<0.001
0.21
0.96
0.18
0.02
0.44
0.07
0.38

0.01

0.10

Centrifugal-Flow
Pump Better

1.00

Axial-Flow
Pump Better

Figure 2. Principal Safety Outcomes in the Per-Protocol Population.
Relative risks of key adverse events, calculated on the basis of the number of events per patient-year in the centrifugal-flow pump group
as compared with the axial-flow pump group, are shown. The per-protocol population included all patients who underwent randomization
and received the assigned device. The relative risk of an adverse event favors the centrifugal-flow pump when the upper boundary of
the 95% confidence interval is less than 1.0. Neither pump is favored when the 95% confidence interval spans the line of unity. The 95%
confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible. Narratives for suspected pump-thrombosis events in the centrifugal-flow pump group are provided in the Supplementary Appendix. P values for relative risk are derived from Poisson regression. Other neurologic events included transient ischemic attack, seizure,
encephalopathy, and neurologic events other than stroke.

Functional Status and Quality of Life

For both groups, there were sustained improvements from baseline in the 6-minute walk test,
NYHA functional class, KCCQ overall summary
score, EQ-5D-5L total score, and the EQ-5D VAS
(Fig. S8 in the Supplementary Appendix). There
were no significant differences in functional-status
test results or quality-of-life measures between the
treatment groups. Sensitivity analyses accounting
for missing values favored the centrifugal-flow
pump group over the axial-flow pump group
with regard to the NYHA classification and the
EQ-5D VAS.
Subgroup Analyses

No interaction between the groups was observed
for the prespecified subgroups of age, sex, race
or ethnic group, intended goal of pump support
(bridge to transplantation or destination ther
apy), or Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) profile with regard to the primary end point. De-

n engl j med 380;17

tails are provided in Figure S9 in the Supplementary Appendix.

Discussion
In this final report of the MOMENTUM 3 trial,
we showed that the HeartMate 3 fully magnetically levitated centrifugal-flow pump was superior
to the HeartMate II axial-flow left ventricular assist system with respect to survival free of disabling stroke or reoperation to replace or remove
a malfunctioning device. In addition to reducing
the need for pump replacement (mostly for pump
thrombosis), the centrifugal-flow pump was associated with a lower incidence of either ischemic
or hemorrhagic strokes of any severity and fewer
bleeding events. We calculate that for every 10 patients who received the centrifugal-flow pump
rather than the axial-flow pump, 2.2 pump-thrombosis events, 2 strokes, and 6.8 bleeding events
(3.6 gastrointestinal bleeds) were averted over a
2-year period. These findings were accompanied
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The

n e w e ng l a n d j o u r na l

by fewer days spent in the hospital at 2 years
among patients who received the magnetically
levitated left ventricular assist device.
Reports of lower stroke rates with the centrifugal pump that were noted in earlier analyses of
this trial were interpreted cautiously, since only
the rates of nondisabling strokes were favorably
influenced.11-14 In the population in the current
analysis, which was 3 times as large, we found
lower rates of both hemorrhagic and ischemic
strokes and a lower rate of disabling strokes.
Stroke rates were not influenced by differences
in baseline rates of atrial fibrillation, anticoagulation regimens, or blood pressure control in our
current or previous analyses.14
The magnetically levitated centrifugal pump
does not degrade high-molecular-weight multimers of Von Willebrand factor to the extent observed with other devices.15 This finding is consistent with the lower lactate dehydrogenase levels
that were found in patients with this pump, which
suggests that less hemolysis was occurring. However, in previous analyses of the MOMENTUM 3
trial, no discernible benefit with regard to the
incidence of mucosal bleeding was noted.10,11 In
this final analysis involving the full trial population, we noted that the centrifugal pump was associated with lower rates of bleeding, including
gastrointestinal bleeding, which is linked with the
unique physiological features of continuous-flow
left ventricular assist devices.16,17 However, a significant residual risk of bleeding persists, which
suggests the need to investigate whether a reduction in the exposure of patients with these
pumps to antiplatelet or anticoagulation therapy
would be beneficial.2,18

of

m e dic i n e

In our trial, infections affecting the drive line
exit site and in other locations occurred frequently, with no significant differences between left
ventricular assist devices. Studies have made note
of aberrant T-cell activation and compromised cellular immunity in patients with older pumps.19,20
Efforts to eliminate the drive line by developing
internally powered durable heart pumps are likely
to be an important advance in this regard. However, vigilance in preventing generalized infections
will remain important.21,22 Late-onset right heart
failure, a leading cause of death, also needs further study.23,24 Outflow-graft twist occlusion, a
unique adverse event with the centrifugal pump,
has been noted previously.25-27 Recognition of this
insidious complication is important, since it compromises pump flow and may mimic pump
thrombosis. A surgical clip to fix the pump outflow graft to the connector is now available to
help prevent outflow-graft rotation.
In summary, in this final analysis from the
MOMENTUM 3 trial, the centrifugal-flow HeartMate 3 left ventricular assist device was associated
with a less frequent need for pump replacement
than the axial-flow HeartMate II left ventricular
assist device and was superior to the axial-flow
pump with respect to survival free of disabling
stroke or reoperation to replace or remove a malfunctioning device.
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